Skip to content

Efficacy prediction and mechanism of transcranial magnetic stimulation for chronic insomnia disorder based on multimodal neuroimaging

Efficacy prediction and mechanism of transcranial magnetic stimulation for chronic insomnia disorder based on multimodal neuroimaging

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054154
Enrollment
Unknown
Registered
2021-12-10
Start date
2021-12-10
Completion date
Unknown
Last updated
2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic insomnia disorder

Interventions

Chronic insomnia disorder (CID) group 1:Transcranial magnetic stimulation
CID group 2:Sham stimulation
Control group:No

Sponsors

Zhenjiang Mental Health Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the icSD-3 diagnostic criteria for chronic insomnia disorders; 2. 18-65 years old; 3. Junior high school or above; 4. Right-handed; 5. Pittsburgh Sleep Quality Index (PSQI) >= 11 points; 6. No insomnia medication or no change in insomnia medication taken in the last 4 weeks; 7. No history of long-term use of anti-anxiety and depression drugs in recent six months; 8. Did not receive physical therapy such as rTMS, transcranial direct current or electroshock in the last six months; 9. No drinking, smoking, coffee, strong tea and other habits, no history of staying up late, shift within two weeks.

Exclusion criteria

Exclusion criteria: 1. Having a family history of mental illness or other mental illness; 2. A history of alcohol, drug or psychoactive substance abuse; 3. Suffering from serious diseases of the medical system, including cardiovascular system, urinary system, respiratory system, digestive system and other serious physical diseases; 4. Pregnant or lactating women; 5. Patients with a history of nervous system, craniocerebral trauma, space-occupying diseases, encephalitis and other organic diseases; 6. Poor efficacy of previous treatment for rTMS.

Design outcomes

Primary

MeasureTime frame
cognitive function;

Countries

China

Contacts

Public ContactSun Jingjing

Zhenjiang Mental Health Center

599308249@qq.com+86 17696031977

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026